Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PepGen Inc.

NASDAQ: PEPG · Life Sciences · 3 alerts · CIK 1835597

PepGen Inc. stories on ALFA USA NewsRead the news →
Share price
$4.19Close, Nov 16
Market cap
$290M
Shares outstanding
69.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PepGen Inc. filings on SEC EDGAR ↗

4:34 PM ET 8-K
Capital Raise

PepGen Capital Raise of $125M

PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.

Value
$125M
8:01 AM ET 8-K
Clinical Trial Data

PepGen Clinical Trial Data

PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.

“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”

James McArthur, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.